Skip to Content
You are currently on the new version of our website. Access the old version .
PathophysiologyPathophysiology
  • Article
  • Open Access

31 October 2026

23 Pages

Signs and Symptoms Suggestive of Inflammatory Latent Herpesvirus Abortive Lytic Replication in U.S. Veterans with Chronic Multi-Symptom Illnesses

,
,
,
,
,
,
,
,
and
1
Department of Chemistry and Biochemistry, University of North Carolina Greensboro, Greensboro, NC 27402, USA
2
Institute for Brain, Behavior, and Immunology (IBBI), The Ohio State University Wexner Center, Columbus, OH 43210, USA
3
Department of Cancer Biology and Genetics (CBG), The Ohio State University, Wexner Center, Columbus, OH 43210, USA
4
Department of Psychological Science, University of North Carolina at Charlotte, Charlotte, NC 28223, USA

Abstract

Background: Chronic multi-symptom illness (CMI) is an idiopathic condition that can cause severe disability in U.S. Veterans. Objective: The collection of data to better characterize and assist in the development of a hypothesis that describes the pathophysiology of CMI. Design: This is an observational VA pilot study of a cohort of 40 U.S. Veterans with CMI. Methods: U.S. Veterans were initially referred to the Rehabilitation Medicine Service (RMS). From this pool of RMS patients, 36 males and four females diagnosed with CMI were selected. Data collected during this study included demographic data, medical history, psychological/cognitive information, and physical exam results. Lab tests were performed twice on the study subjects. Lab tests included serum 25(OH)D3 levels, calcium levels, and human serum IgM and IgG antibody levels to three herpetic virus dUTPase. Serum 25(OH)D3 levels were examined because active vitamin D has a role in immune system function, including the suppression of latent viruses and the modulation (attenuation) of the immune system’s inflammatory response. Herpesvirus dUTPases are proteins that are produced during viral DNA replication but are not structural components of virions. Human antibodies to dUTPase proteins were used as biomarkers for abortive lytic viral replication, a process that can stimulate an inflammatory immune process. Results: In our study subjects, the most common symptom was chronic pain (95%), the most common sign was hyperalgesia to pin prick (95%) and the most serious diagnoses were quadriparesis and neurocognitive decline in two study subjects. Conclusions: The clinical findings together with previous vitD and dUTPase serology studies suggest a possible association with low vitD levels, inflammatory elevated herpesvirus abortive lytic replication and CMI.

1. Introduction

Since 1990–1991, many U.S. military service members returning from the wars in Iraq and Afghanistan have suffered chronic, often disabling, multi-symptom illnesses for which the pathophysiology or etiology of their symptoms is unknown [1,2,3,4]. Based on a wide range of epidemiological studies, chronic multi-symptom illness associated with the first Gulf War affected at least one quarter (range 25% to 32%) of the U.S. Service members who served in the Gulf War region during the 1990 to 1991 time frame [1]. Currently, the Department of Veterans Affairs defines chronic multi-symptom illnesses (CMIs) as illnesses with clusters of often disabling symptoms (including chronic pain, fatigue, headaches, indigestion, insomnia, dizziness, respiratory disorders, and memory problems) for which an underlying cause or causes have not been determined [5].
Multi-symptom illnesses such as Gulf War Illness (GWI) and myalgic encephalomyelitis (ME)/chronic fatigue syndrome (CFS) have been a vexing problem for many U.S. Veterans as well as others suffering from these illnesses. These symptom-based illnesses often include chronic severe pain. Medical management of these multi-symptom illnesses has likewise been a frustrating experience for many medical providers. Similar illnesses have been documented in U.S. Service members since the U.S. Civil War [6].
This pilot study was initiated based in part on a latent viral immune inflammatory response model for chronic multi-symptom illnesses. This study was also based on the findings of frequent early chronic multi-symptom illness among returning U.S. Marines from Iraq and Afghanistan between 2010 and 2011 [7,8]. Young U.S. Marines often returned with signs of hyperalgesia in response to a pinprick skin test and signs of decreased balance on the Tandem Gait Test. These two abnormal signs were associated with the symptom of tinnitus and with deficient and insufficient levels of the stored active vitamin D precursor, 25(OH)D3.
This current study builds on previous data demonstrating increased levels of antibodies against deoxyuridine triphosphate nucleotidohydrolase (dUTPase) of multiple herpesviruses in the serum of U.S. Veterans [9,10,11,12,13,14,15,16]. Current study U.S. Veterans were diagnosed with chronic multi-symptom illnesses, including chronic fatigue syndrome and Gulf War Illness [16]. Specific human IgM and IgG herpetic virus dUTPase antibodies indicate the presence of antigenic herpetic virus dUTPase. These proteins stimulate an inflammatory immune response in the tissues where they are expressed, such as within the cells of the nervous system. The dUTPase proteins are expressed during herpetic virus lytic and abortive lytic replication.
Distinct or unique dUTPases are present in different life forms, including some viruses, bacteria, fungi, plants, animals, and humans. Herpetic virus dUTPases occur in a monomeric form. Reactivation of herpetic viruses may result in the expression of the dUTPases, which stimulate the immune system. The resulting inflammatory response includes the generation of specific human antibodies directed against them [14]. The main function of the dUTPase in different organisms, including latent herpetic viruses, is to produce dUMP for synthesizing DNA. A second purpose is to remove dUTP from the deoxynucleotide pool. This, in turn, can help to reduce the possibility of dUTP being erroneously incorporated into an organism’s DNA [17]. Human anti-herpesvirus dUTPase IgM and IgG antibodies in the serum were used in this study as biomarkers. Their purpose is to indicate the past and current presence of inflammatory herpetic virus dUTPases in the nervous system and other tissues of the body [16].
Human herpesvirus dUTPase IgG and IgM antibody levels, measured during this pilot study from each of the three subfamilies of herpetic viruses (alpha, beta, and gamma Herpesviridae), were reported in a previous article [16]. The herpes virus dUTPase proteins are recognized as antigenic to the human immune system and are inflammatory [11,13,15]. In this study, human herpetic virus IgG and IgM dUTPase antibody levels were measured to alpha-Varicella Zoster (VZV; ORF8), beta-Human Virus 6 (HHV6; U45), and gamma Epstein–Barr (EBV; BLLF3) viruses.
Rather than the complete reactivation of latent virus during lytic replication, the study participants are proposed to have a new virus inflammatory response disease. It is characterized by the synthesis of antigenic inflammatory molecules during abortive lytic replication [18,19]. With this newly recognized form of viral illness, there is generally no fever, no elevated white blood cell count, or other typical signs of an acute viral infection. Rather, the inflammatory response is characterized by the presence of specific IgG and IgM antibodies and an accompanying inflammatory (cytokine) response to a molecule produced during viral replication.
In this study, the measurement and presence of human IgG and IgM antibodies to specific herpesvirus dUTPase proteins are used as biomarkers and as documentation for this proposed newly recognized mechanism of viral illness [16]. Symptoms and physical exam findings are used to characterize the effect and location of the latent virus inflammatory response. Because certain herpetic latent viruses, especially Varicella Zoster and herpes simplex viruses 1 and 2, are present in the nervous system, inflammation affecting nervous system cells/tissues is proposed to initially cause hyperexcitability in the affected cells, followed by damage and even cell death. For example, tinnitus and decreased balance are symptoms that suggest the middle ear as a focus of an inflammatory response. Similarly, neuropathic pain and hyperalgesia in response to a pinprick skin test point to the cells of the sensory ganglia and above as the point of inflammation.
Herpesviruses are large DNA viruses. Of the three herpesviruses examined in this pilot study, EBV has the smallest coding capacity, and it encodes for at least 80 proteins, which are expressed during lytic (abortive lytic) replication. HHV-6 and VZV encode for more proteins; however, similar to EBV, these proteins are expressed during lytic (abortive lytic) replication.
Latent (Latency) [20,21] and lytic (abortive lytic) [22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41] replication are states in which herpes viruses exist. In latency, only a few viral genes are expressed, which allows the virus to avoid the host immune system and to persist for the lifetime of the individual. In latency, the virus does NOT replicate its DNA, and thus no new virus is formed.
If something triggers the latent virus, it reactivates, which means it enters the lytic (abortive lytic) state. In the lytic state, a different set of genes is expressed in a cascade manner (alpha, beta, and gamma genes). If all genes are expressed, this process results in a new virus being formed, which is termed a PRODUCTIVE INFECTION. If, for some reason, this process of lytic replication is not completed, no new virus is formed, and the state is referred to as an abortive lytic. However, some viral proteins, such as dUTPase, are expressed during abortive lytic replication. Abortive lytic replication is really what happens when you treat a patient with acyclovir. Acyclovir inhibits viral DNA elongation, thus preventing new viruses from forming, but it does not prevent the expression of alpha or beta genes and thus dUTPase proteins are made. It is possible that herpes virus abortive lytic replication can occur simultaneously in the same nervous tissue as a variable and perhaps small amount of lytic replication. This might result in a significant amount of inflammation but without a significant amount of cell lysis.
A small observational pilot study of U.S. Veterans with chronic multi-symptom illness (CMI) was conducted at the W.G (Bill) Hefner VA Medical Center between 2019 and 2025 in Salisbury, North Carolina. This study involved the collection of a significant amount of demographic, medical, psychological, and symptom history. A physical exam and cognitive and psychological testing/evaluations were performed at the beginning of this study. Two sets of blood samples were drawn and tested over the course of this study. Each set of blood tests included the measurement of serum calcium and vitamin D precursor, 25(OH)D3, levels, multiple inflammatory cytokine levels, and three specific herpes virus dUTPase enzyme IgM and IgG human antibody levels. Cytokine and herpes virus human dUTPase antibody level blood test results are presented in greater detail in a separate report [16].
This report focuses on demographic information and medical history, including concurrent diagnoses, physical exam findings, and the psychological and cognitive testing conducted in the study subjects from this VA pilot study. Also included is how the clinical findings relate to our previous lab findings [16] for 25(OH)D3 and our study subjects’ herpes virus dUTPase human antibody test results.
This report also explores how vitamin D status and latent herpetic viruses may interact in the pathophysiology of chronic multi-symptom and system illnesses. This study’s findings support the hypothesis that some idiopathic chronic multi-symptom and system illnesses have an underlying pathophysiology related to the body’s immune system’s inability to suppress abortive lytic replication of latent herpesviruses. The immune system’s inability to suppress herpes virus abortive lytic replication is hypothesized to result in an inflammatory response in cells where the latent herpesvirus DNA resides.

2. Methods

This study was approved by the Salisbury VA Medical Center Investigational Review Board (IRB) and Research Committee, IRB Protocol 18-020, Project No. 1575420-4.

2.1. Patient Selection

The study population was drawn from U.S. Veterans who receive medical care from the W.G. Hefner VA Health Care System in Salisbury, N.C. Patients who met the study criteria were then referred for consideration for this study. From this RMS input of patients, 36 U.S. male and 4 female Veterans with chronic multi-symptom illnesses were selected to participate in this pilot study.
Inclusion Criteria: U.S. Veterans (male and female) treated by the W.G. Hefner VA Health Care System who have some of the idiopathic symptoms of chronic multi-symptom illnesses described in Section 1 were eligible for this study. Specific inclusion criteria for symptomatic Veterans in this pilot study included the presence of at least one sign during a physical exam involving the nervous system (i.e., hyperalgesia in response to a pinprick skin test, hyperhidrosis, decreased balance, increased reflexes, etc.) and at least two associated symptoms (physical, psychological, or cognitive symptoms, such as significant neuropathic or musculoskeletal pain, fatigue, dyspnea, anxiety, depression, etc.).
Exclusion Criteria: U.S. Veterans who were unable to give voluntary informed consent for either cognitive or psychological reasons were excluded from this study. Veterans who were unable or unwilling to undergo the required blood testing were also excluded from this study.

2.2. Demographic, Medical, Psychological, and Symptom History

Demographic, medical, psychological, and symptom histories were obtained using a questionnaire and the VA electronic medical record. These histories were then reviewed by the examining physician. The medical history in this report contains the following five parts: concurrent medical diagnoses, history of viral infections, trauma history, medications, and symptoms. Psychological information was obtained through interviews and testing by two neuropsychologists. Wherever possible, information collected was verified through the VA patient electronic medical record. A complete list of symptoms is included in Supplementary S1.

2.3. Physical Exam

A physical exam was performed once by a single VA medical provider upon the initial encounter with the 40 VA pilot study participants. Additional physical exams were performed over the course of this study in two study participants whose physical condition changed dramatically. The complete findings of the initial physical exam are listed in detail in Supplementary S2. The physical exam is an important component of the evaluation of U.S. Veterans with chronic multi-symptom illness. Unlike symptoms, components of the physical exam are meant to be findings that can be more objectively and consistently measured over time, between different examiners, and across different patient populations. When the objective findings of a physical exam fall outside of an accepted norm, they can be referred to as abnormal signs.
The purpose of the physical exam was to determine a profile of abnormal signs in our group of U.S. Veterans with chronic multi-symptom illness. There was a specific focus on any signs related to the somatic and autonomic nervous systems and on nervous system reflexes, including the gag reflex, the glossopharyngeal nerve (cranial nerve IX), the vestibulocochlear nerve (cranial nerve VIII) and balance, and deep tendon reflexes in the extremities.
Pain is a very common symptom in patients with chronic multi-symptom illnesses. Pain is a symptom that can be very subjective depending on the patient’s interpretation of the pain sensations. Alternatively, the patient’s reaction to a light pinprick on the skin or touch is more objective. Hyperalgesia is an abnormal sign of increased sensitivity to a pinprick skin test. It most often occurs over the skin of the neck or back and corresponding limbs, and it may represent an inflammatory reaction affecting the sensory ganglia of the spine. It is also possible that hyperalgesia originates further up in the sensory pathways of the central nervous system. Similarly, allodynia is a painful reaction to light touch over skin covering some parts of the body but not others. Allodynia can be dramatic and can represent an objectively abnormal sign but is less common.
A complaint of dizziness or decreased balance can be quite disturbing; however, it is a subjective complaint. A staggering gait on heel-to-toe walking along a straight line (the Tandem Gait Test) can be a dramatic objective sign of decreased balance, especially if visual feedback is taken away and the patient must rely on their vestibular system of the middle ear to accomplish this task.
To look for objective signs during a physical exam in this study population, our study subjects underwent an examination of motor and sensory function in the somatic nervous systems and evaluation for other signs in the autonomic nervous system, such as hyperhidrosis and hyperemia of the skin. The skin and oral cavity mucosa were also examined for rashes or intraoral lesions that represent signs of inflammation. In our U.S. Veteran population, abnormal signs involving the nervous system are often associated with a variety of symptoms that are perceived and interpreted by the brains of our U.S. Veterans with chronic multi-symptom illnesses. The evaluation of parts of the peripheral nervous system was a major focus for this W.G. Hefner VA pilot study.

2.4. Description of Psychological and Cognitive Evaluation and Testing

Measures of cognitive and psychological function were obtained using the following assessment tools:
Montreal Cognitive Assessment (MOCA)
The MoCA is a cognitive screening test that takes less than 10 min to administer and includes items covering orientation, attention, memory, visual-spatial ability, language, and executive functions [42]. Scores range from 0 to 30, with lower scores indicating poorer performance. An abnormal total score is below 26. Additionally, age and education norms have been published [43], which were also used in this study in addition to the total raw score.
Conners Continuous Performance Test, 3rd Edition (CPT-3)
The CPT-3 is a computerized test that utilizes a visual continuous performance paradigm to assess complex attention abilities among individuals aged 8 to 89, including vigilance, impulsivity, inattention, and sustained attention [44]. Administration takes 14 min, during which the examinee presses the space bar following presentation of target letters and inhibits response when the non-target letter appears. The nine primary scores used were gender-based T scores with a mean of 50 and standard deviation of 10, in which higher T scores generally indicate worse performance except for Hit Reaction Time (HRT). The clinical likelihood estimate is a score based on the number of T-scores that are elevated as well as the magnitude of elevation. The clinical likelihood estimate was used as the primary outcome, and it indicates the likelihood of having a disorder characterized by attention deficits as very high, high, moderate, or minimal. Additionally, the CPT-3 includes a validity indicator based on the detection of a timing issue, an individual producing insufficient number of hits, or respondents making more than 25% omission errors. Age-based, non-gendered norms were used.
DSM-5 Self-Rated Cross-Cutting Symptoms Level 1, Adult (DSM-5 XC)
The DSM-5 Level 1 is a 23-item measure of various psychiatric symptoms that allows the user to screen for 13 different DSM-5 syndromes [45]. Respondents rate reach symptom on a 5-point Likert-like scale of frequency, from 0 (not at all) to 4 (severe), as applied to the prior two weeks. This measure was used as a descriptive measure.
DSM-5 Self-Rated Somatic Symptoms Level 2, Adult (DSM-5 Somatic)
The DSM-5 Somatic measure is a 15-item measure of physical complaints [46]. Each item is rated based on how much the respondent has been bothered by that symptom over the prior 7 days, as not at all, a little, or a lot. Higher scores reflect more physical complaints.
DSM-5 Self-Rated Anxiety Scale Level 2, Adult (DSM-5 Anxiety)
The DSM-5 Anxiety measure is a 7-item questionnaire of anxiety symptoms [47]. Respondents consider the prior 7 days as they rate the frequency of each symptom from 1 (never) to 5 (always). The total score is converted to a T score using a provided table, with higher scores indicating worse anxiety.
Neurobehavioral Symptom Inventory and Mild Brain Injury Atypical Symptom Scale (NSI + MBIAS)
The NSI is a 22-item self-report questionnaire of assessing the severity of somatic, cognitive, and affective symptoms over the prior two weeks [48]. Total scores range from 0 to 88, with higher scores indicating more severe symptom burden. The Mild Brain Injury Atypical Symptoms (mBIAS) contains five rationally derived items determined to be uncommonly endorsed following concussion [49]. Each item is rated from 1 to 5, resulting in a total score range of 5 to 25 with higher scores indicating invalid symptom reports.
The Pittsburg Sleep Quality Index (PSQI)
The PSQI is a nine-item questionnaire that provides a global sleep quality score ranging from 0 to 21 [50]. Sleep quality is rated based on the past month, with greater scores indicating poorer sleep quality.

2.5. Procedure for Cognitive and Psychological Testing

Participants completed the cognitive and psychological tests in person and in an individual setting. Procedures were briefly described to the participant before beginning. The CPT-3 was administered and scored via the commercially available software; the test was administered on a laptop dedicated for research purposes. The MoCA and self-report measures were completed using traditional pen and paper format. Standardized procedures were used for all tests. Scores were imputed into an Excel sheet by the neuropsychologist completing the testing. All analyses were completed using SAS 9.4m7 Enterprise Guide. Kruskal–Wallace tests were used due to size differences across vitamin D groups, the size of the groups, and violation of normality. Alpha was set at 0.05. Given the small size of this pilot sample, corrections were not made for multiple comparisons.

3. Results

3.1. Demographic and Other Participant Data

Table 1 and Table 2 show the demographic data. Study participants were predominantly male (90%). The median age was younger than that of the entire veteran population and the sample was made up of a higher % of veterans who had served in combat. There was a higher percentage of US Marines among our study subjects than in the overall US Veteran population. Finally, our study participants had a significantly high frequency and average rate of service-connected disabilities. In Table 2, the first column represents the combined percentage of compensable disability, and the second column represents the number of study subjects who had this level of compensable disability in our group.
Table 1. VA pilot study participant characteristics and demographics compared with those of the entire U.S. VA population.
Table 2. Service connection status of the study sample.

3.2. Occupation Type or Status

Occupation Type or Status: Skilled trade: 10; admin/clerical/sales: six; transportation: four; professional: four; self-employed: one; general laborer: one; disabled: five; retired: five; and none listed: four.

3.3. Social and Other Habits

This section reports on the use of tobacco, alcohol, and illicit drug use which can negatively affect our study subjects’ mental and physical health. It also reports on the use of sunscreen which is beneficial in avoiding skin cancer, but which is detrimental to maintaining adequate vitamin D, 25(OH)D3, precursor storage.
Self-Reported Tobacco Use: Never: 18 (45%); previous: seven (17.5%); and current—cigarettes: 12 (30%), oral: three (7.5%), and oral plus cigarettes: two (5%).
Self-Reported Alcohol Consumption: No alcohol: 27 (67.5%); three (1–2 drinks/day—7.5%); six (4–7 drinks/day—15%); two (12–15 drinks per day—5%); and two (26–28 drinks per day—5%).
Self-Reported Illicit Drug Consumption: None: 38 (95%); one (one drug—2.5%); and one (six drugs—2.5%).
Self-Reported Sunscreen Use: Often: 12 (30%); seldom: 12 (30%); and never: 16 (40%).

3.4. Medical History Summary—Self-Reported and from the VA Electronic Health Record (EHR) (See Supplementary S1. For the Complete Data Set)

The medical history presented in this manuscript consists of the following five parts: non-mental health medical diagnoses, history of viral infections, trauma history, medications, and symptoms. After chronic multi-symptom illness, the most frequent concurrent medical diagnosis made in our study population was a history of trauma as follows: to the extremities excluding the hands and feet (75%), to the head and neck (45%), and to the hands and feet (37.5%). Following trauma, the most frequent diagnoses included history of chickenpox (varicella) and/or shingles (Zoster) (70%), arthritis (57.5%), hypertension (52.5%), mild traumatic brain injury (TBI) (50%), gastroesophageal reflux disease (GERD) (45%), and obstructive sleep apnea (OSA) (25%).
The medications most frequently prescribed to study subjects were for pain and included the following: oral and topical anti-inflammatory meds: oral (45%), topical (22.5%); antiseizure meds for nerve pain (27.5%); muscle relaxers (17.5%); and narcotics (10%). Prescribed pain medications by frequency were as follows: mental health disorder meds (40%); hypertension and gastroesophageal reflux (GERD) meds (37.5% each); sleep meds (15%); and anti-viral and migraine headache meds (12.5% each). The most frequent over-the-counter nutritional supplements prescribed/recommended included vitamin D3 (72.5%), omega 3 fatty acids (42.5%), and other nutritional supplements including multi-vitamins (42.5%).
The most frequently reported symptom was pain. The median chronic pain level was 5 on a scale of 1–10 and chronic pain occurred in 95% of the study subjects. Chronic nerve pain was reported by 77.5% of the study subjects, and chronic joint pain was reported by 90% of the study patients. More severe acute exacerbations of pain (the median pain level was 7 on a scale of 1–10) were reported by 95% of the study patients, with 77.5% of the study subjects reporting nerve pain exacerbations and 92.5% reporting exacerbations of joint pain. Two study subjects (5%) reported no significant pain symptoms.
Pain symptoms were usually the reason for referral of these study subjects to the VA Rehab Medicine Service (RMS) and ultimately part of the reason for referral to the RMS Chronic Multi-Symptom Illness VA pilot study. Tinnitus was the next most frequent symptom in the study group (82%), followed by chronic fatigue (80%), sleep disturbance (75%), and GI symptoms (72.5%). This distribution of symptoms is consistent with a profile of chronic multi-symptom illness symptoms, except for tinnitus, which is usually not elicited from study subjects unless specifically requested.

3.5. Physical Exam Summary (See Supplementary S2 for the Complete Data Set)

The majority (60%) of our study population had a BMI of 30 or more and were obese. Just less than one-third of our study population had a dark complexion. These two findings can contribute to low 25(OH)D3 vitamin D precursor (storage) levels in the serum. In our study group, 45% of the participants had some form of skin rash; one-third of these skin rashes were moderate, and 7.5% of these cases had an intra-oral lesion. These signs may indicate an inflammatory process going on in the skin and oral mucosa.

3.6. Vascular and Autonomic Nervous Systems

The physical exam results showed that 27.5% (11) of the study subjects exhibited stage 1 (systolic BP 130–140 mmHg) or stage 2 hypertension (systolic BP > 140 mmHg) and 30% (12) exhibited diastolic hypertension only (BP > 80 mmHg). Study participants blood pressure (BP) ranges (definitions) are based on blood pressure stages per the American Heart Association [57]. Ten percent (four) of the study patients had both systolic and diastolic hypertension. Of the above, 57.5% (23) of U.S. Veterans who were documented to have hypertension based on the physical exam conducted at the beginning of the study, only 37.5% (15) were on treatment for hypertension at the time their blood pressure was recorded. This group of treated Veterans included all those with systolic hypertension, except for one Veteran who had not previously been diagnosed with hypertension.
In our study group test of going from supine to standing, 7.5% of the study subjects demonstrated orthostatic systolic hypotension (drop of 20 mmHg points or more), and an additional 7.5% exhibited slightly smaller drops of 15, 17, and 19 points. Furthermore, 7.5% of the study subjects experienced diastolic orthostatic hypotension with a drop of 10 mmHg points or more.
In our study group, 20.5% of the study subjects were noted to have hyperhidrosis in either the palms or soles based on the physical exam. Two study participants (5.1%) exhibited hyperemia in the skin of either the head and neck area or the extremities.

3.7. Motor System

Deep tendon reflexes in 5% of the study subjects were increased in the upper extremities and in 15.4% of the lower extremities (>3/4). Gag reflexes were increased in 20% of the study subjects. In the study group, 10.3% were unable to walk on their tip toes and heels. Seven (17.4%) of the study subjects, including a double lower extremity amputee, were unable to perform a deep knee bend.
In those subjects who could perform the Tandem Gait Test (walking heel to toe along a straight line 10–15 feet forward and backward), the results were normal in 28.9% of the study subjects when the test was performed with the eyes open, and in only 2.7% when performed with the eyes closed. In those who could perform this test, it was impaired in 52.6% when performed with the eyes open, and in 56.8% when performed with the eyes closed. This test could not be performed with the eyes open in 18.4% of the subjects and with the eyes closed in 40.5% of the subjects.
Motor system diagnoses made after the initial physical evaluation (exam) were as follows: quadriparesis 2/40 (5%) of the study subjects, diagnosed in September of 2022 and in October of 2024.

3.8. Sensory System

Sensation to light touch was intact or normal in the skin of the upper extremities in 97.5% of the study subjects; intact or normal in the skin of the right lower extremity in 87.2% of the study subjects; and intact or normal in the skin of the left lower extremity in 84.6% of the study subjects.
Exaggerated painful sensation to a pinprick skin test (hyperalgesia) was elevated in the skin of 95% of the study subjects’ upper extremities and in the skin of 82.1% of the study subjects’ lower extremities. The skin over the cervical spine was hyperalgesic in response to a pinprick skin test in 77.5% of the study subjects, and the skin over the lumbar spine was hyperalgesic in 85% of the study subjects.

3.9. Mental Health Data Summary

A summary of the participants’ self-reported mental health history is provided in Table 3.
Table 3. Psychological diagnosis listed in the study subjects’ VA electronic medical record and on their questionnaire form.

3.10. Cognitive Function Test Results

Table 4 presents the summary statistics for the cognitive measures. Using a conservative mBIAS cutoff score, 3 individuals were invalid and 2 were missing mBIAS data; thus, 35 were included for evaluation on symptom questionnaires. On average, the sub-sample with valid cognitive data showed a vitamin D level that was in the “low” range (Med = 23.8). Although the sample showed average global cognitive ability on the adjusted MoCA total score (Med = 54.0 T), about half the sample showed at least a moderate likelihood of having a disorder characterized by attention deficits on the CPT-3 clinical likelihood estimate; however, the majority were in the Moderately Likely range as opposed to having a Highly or Very Highly likely chance of having an attentional disorder. Group differences were used to compare those with deficient, low, or normal vitamin D levels. None of the group’s scores were significantly different for the MoCA total score (both raw and adjusted T) nor the CPT-3 classification variable.
Table 4. Descriptive statistics for global cognitive variables (n = 37).

3.11. Psychological Outcome Test Results

Within the study group, the psychological tests revealed depression (74%), anger (65%), anxiety (60%), memory complaints (57%), and substance use issues (57%) in most of our study subjects. In both the cognitive function and psychological outcome test results, there were no correlations with serum 25(OH)D3 levels. Using the DSM-5 Cross-Cutting Symptom Measure in the combined sample, there were significant elevations (>50%) for depression (74%), anger (65%), anxiety (60%), somatic symptoms (71%), sleep disturbance (77%), memory complaints (57%), and substance use issues (57%). Table 5 shows the percent of each symptom cluster endorsed on the DSM-5 XC, as well as the percent reporting the symptoms by history, and a column showing the percent reported in [58]. In general, the percentage of our sample reporting symptoms was much higher than in the meta-analysis.
Table 5. Comparison of self-reported psychiatric symptoms.

3.12. Trials 1 and 2: Human dUTPase Antibody Serum Test Results in Two Study Subjects Who Were Later Diagnosed with Severe Neurodegenerative Disorders Within 3–5 Years After Starting This Study

Significant neurodegenerative conditions were diagnosed in two study subjects after this VA pilot study reopened and after their Trial 2 blood tests had been collected. One study subject was diagnosed with Amyotrophic Lateral Sclerosis in September 2022 and was monitored at the Atrium Health Wake Forest Baptist ALS Clinic until his passing in hospice care on 20 June 2025. In addition to ALS and quadriparesis, he had two other significant diagnoses. The first diagnosis was “Major or Mild Neurocognitive Disorder Due to Unknown Etiology”. The second diagnosis was terminal metastatic appendiceal cancer (diagnosed in December 2019 after his appendix ruptured and 8 months after entering our study). Serum IgG and IgM human antibody levels against Varicella Zoster dUTPase were both positive (elevated) in both his serum blood draws (Trials 1 and 2).
The second study participant developed a progressive, neurodegenerative disorder that included quadriparesis with some sparing of the left upper extremity and a rapidly progressing decline in cognitive function, which was diagnosed as a “Major or Mild Neurocognitive Disorder Due to Unknown Etiology” during 2024–2025. He was evaluated at the Duke University Health Neuromuscular Clinic in August 2025. He currently requires further neurological evaluation to determine a more precise diagnosis for his neurodegenerative disorder. IgG human antibody levels against the Varicella Zoster dUTPase were elevated/positive in both blood draws (Trials 1 and 2). The IgM human antibody levels against the Varicella Zoster dUTPase was elevated/positive in the first blood draw only (Trial 1).
The data for Varicella Zoster in these two study subjects is presented because this is an observational VA study of Veterans with chronic multi-system Illness (CMI); the above-described diagnoses were very unexpected observations in these two VA pilot study subjects with a CMI initial diagnosis (see Section 4 below).

4. Discussion

Based on earlier work [7,8,9,10,11,12,13,14,15], this VA pilot study was designed to provide a multi-perspective snapshot of U.S. Veterans with chronic multi-symptom illnesses. Our VA pilot study group had higher exposure to combat and higher VA compensation and pension ratings (higher disability) than the general VA population, even when compared with Veterans who have served since 9 November 2001. For unknown reasons, the African American/Black racial makeup of our study population was nearly twice that of the general U.S. Veteran population [51,56].
Most Veterans in our study were service-connected for both physical and psychological impairments/disabilities, which may be a common feature of CMI. Our study’s 29 combat Veterans served in multiple wars and conflicts since the Vietnam War; thus, CMI is not only a result of recent wars involving Iraq and Afghanistan. Based on earlier studies conducted following the first Gulf War, CMI likely dates to at least the U.S. Civil War [6].
The most frequent past medical diagnoses were episodes of trauma, which is not surprising given the nature of serving in the military and in combat. The history of chickenpox (varicella) and/or shingles (Zoster, 70%) is also not surprising; it is significant in that the presence of latent VZV in the body provides a basis for the possible presence of VZV abortive lytic replication as one source of inflammation causing neuropathic pain in 77.5% of U.S. Service members with CMI. Tinnitus was the next most frequent symptom in the study group (82%), followed by chronic fatigue (80%), sleep disturbance (75%), and GI symptoms (72.5%). This distribution of symptoms is consistent with a profile of chronic multi-symptom illness [5], except for tinnitus, which is usually not elicited from patients unless asked about specifically.
Our physical exam focused on the nervous system due to the hypothesis that many, if not most, of the signs and symptoms in our U.S. Veteran CMI study group emanate from the nervous system. Our hypothesis is that CMI signs and symptoms are primarily related to an immune system inflammatory response to the reactivation of latent herpesvirus which results in abortive lytic replication rather than predominately lytic replication occurring in nervous system cells. The inflammation caused by dUTPase, and possibly other molecules produced during abortive lytic replication, is proposed to be the cause of the symptoms and signs recorded during physical exams in our study subjects with CMI.
The DNA of herpetic viruses, especially Varicella Zoster and simplex viruses, has been found throughout the central and peripheral nervous systems affecting the brain, cranial nerves in the brain stem, and the peripheral nervous system, including the autonomic and somatic nervous systems [59,60]. The reactivation of latent herpetic viruses, especially Varicella Zoster, has been reported to be associated with a failure of the immune system to suppress these viruses. The pain caused by reactivation of Varicella Zoster has been attributed to inflammation of the sensory ganglia and nerves [61]. The neuropathic pain of Varicella Zoster can be associated with hyperalgesia with a pinprick skin test and allodynia. This pain is not always associated with skin lesions or rash, and when this occurs, the condition is referred to as “zoster sine herpete” [62]. Finally, motor nerves can be affected during an outbreak of herpes zoster or simplex, causing weakness or paralysis of certain muscles, such as those of the brachial plexus or face [59,60].
The physical exam results showed that hyperalgesia in response to a pinprick skin test of the upper extremities was the most frequent abnormal sign, which was found in 95% of the study subjects. Hyperalgesia in response to a pinprick skin test may be a manifestation of acute zoster, postherpetic neuralgia, and zoster sine herpete as well as other herpetic viruses, such as herpes simplex viruses 1 and 2 [63,64]. Hyperalgesia in response to a pinprick skin test is a very frequent abnormal sensation in the skin of our study subjects and is commonly associated with one of the three herpes virus dUTPase proteins (VZV) whose antibody levels were measured in a previous study [16]. The VZV herpetic virus dUTPase antibody levels were found to be positive/elevated in at least one of the two blood specimens drawn from each study subject who had two blood draws (36/40). Hyperalgesia in response to a pinprick skin test may also be connected to the symptom of neuropathic pain, which was reported to be present in 77.5% of the study subjects.
The next frequent abnormal sign recorded during the physical exams was impaired balance on heel-to-toe walking along a straight line (Tandem Gait Test). A high prevalence of the latent (alpha) herpes simplex virus 1 (HSV-1) DNA has been reported in the trigeminal geniculate and in the vestibular ganglia–vestibulocochlear nerve (cranial nerve VIII) [65]. The sign of decreased balance in at least 71% of our study subjects and the symptom of tinnitus reported to be present in 82% of the study subjects may be related to HSV-1 virus, whose dUTPase was not measured in this study.
No study subjects on the initial physical exam had what appeared to be a rash consistent with shingles, although many different, atypical-appearing rashes have been documented to be associated with herpetic virus DNA [66]. Herpetic virus dUTPase protein levels have not yet been measured in serum; only anti-dUTPase antibodies have been documented. However, HHV-6 antigens and EBV dUTPase protein have been recently detected in postmortem brain tissue of individuals with chronic fatigue syndrome [67].
Initial testing of cognitive function did not reveal significant impairment other than moderate attention deficit disorder in about one half of our study subjects. Vitamin D status was not related to cognitive functioning on objective measures. Psychological testing revealed the presence of moderate to high levels of psychological complaints, including depression, anger, anxiety, somatoform, and sleep disturbance symptoms. This is consistent with the frequent presence of anxiety, depression, and PTSD in individuals with CMI.
The measurement of the active vitamin D precursor, 25(OH)D3, was included in our study because low vitamin D precursor storage states have been found in Veterans with chronic multi-symptom illnesses. [8] Active vitamin D may play a significant role in the suppression of latent viruses and in the mitigation of the inflammation associated with viral antigens. [8,68,69,70] The guidelines used in this study for assessing 25(OH)D3 levels have been recommended by the Endocrine Society [71]. When comparing the serum 25(OH)D3 levels in the study participants at various times of the year, their test results were converted to seasonally adjusted annual mean serum 25(OH)D3 levels using the “25 Hydroxyvitamin D Calculator for Seasonal Adjustment” developed at the Kidney Research Institute, University of Washington. In references [72,73], serum 25(OH)D3 levels and the storage of this active vitamin D precursor go up or down in response to the rate of 25(OH)D3 utilized by the body to make active vitamin D, the amount of 25(OH)D3 being synthesized by the body from sunlight, the amount introduced into the body from D3 supplementation, and the amount of 25(OH)D3 degraded or gotten rid of by the body [74]. The level of storage of the precursor to active vitamin D can be viewed as analogous to the charge on a battery. When the demand for active vitamin D increases significantly and the level of vitamin D precursor storage is adequate or even high, the precursor level will drop unless it is adequately replaced. Conversely, when demand for active vitamin D is low, low storage of the precursor (battery charge) is adequate. However, when the demand for active vitamin D increases, a higher level of vitamin D precursor (battery charge) is needed to produce sufficient active vitamin D during certain stressors such as pregnancy, trauma, or infection [74].
There were significant numbers of insufficient and deficient levels of active vitamin D precursor among our study participants, despite the knowledge of low vitamin D status early in this study and treatment by their physicians. In the 36 study subjects that had two blood draws, the serum 25(OH)D3 levels of 25 study subjects increased (average 18 points), the levels of 10 study subjects decreased (average 10 points), and one subject’s level remained the same. [16] This reflects an overall improvement in vitamin D status between the first and second blood draws that was statistically significant on the paired sample test (Table 6). The definitions of sufficiency, insufficiency, and deficiency were established with respect to bone health and not immune system health. The levels of required stored vitamin D to make active vitamin D may change significantly depending on an individual’s changing physiological status.
Table 6. Paired sample test (paired differences) for adj. vit. D and Ca levels.
Using the Pearson correlation, the levels of the non-seasonally adjusted vitamin D precursor, 25(OH)D3, in Table 7 did not correlate with serum calcium levels in each trial. In a previous larger study describing the effect of 25(OH)D3 on serum calcium, the Pearson correlation between the two measurements was 0.46 among men and 0.40 among women, suggesting a moderate day-to-day variation in calcium intake [75]. This correlation level may be expected because active vitamin D controls calcium absorption and not its precursor. Moreover, 25(OH)D3 levels in the serum do not correlate with active vitamin D levels in the serum, except at very low 25(OH)D3 levels [74]. The fact that the effect of 25(OH)D3 on serum calcium levels was not observed could also be due to the small sample size in our study.
Table 7. Relationship between vitamin D3 and calcium in Trials 1 and 2.
There is growing evidence that abortive-lytic herpes virus reactivation may be a commonly unrecognized pathological process resulting in an immune inflammatory response in tissues where latent herpes viruses reside. Latent Varicella Zoster and herpes simplex viruses are known to reside in nervous system tissue and are known to cause severe pain. They are also known to cause encephalitis and lower motor neuron impairment [59,60].
A previously published herpes virus dUTPase serology study [16], which included our pilot CMI and Gulf War Illness Veteran cohorts, found an increased prevalence of IgG (55% and 83%, respectively) and IgM (80–90% and 100%) dUTPase antibodies against multiple herpes viruses in the patient study cohorts relative to the controls (5% and 7% for IgG and IgM, respectively, p < 0.001) [16].
An independent study of postmortem brain tissue in patients with chronic fatigue syndrome supports the concept of multiple herpetic viruses being active at the same time in the nervous system [67]. Interestingly, in this postmortem study of brain and spinal cord tissue, active latent EBV and HHV-6 herpesviruses co-existed in the same patient with chronic fatigue syndrome but not in the same tissue locations within the brain and nervous system.
Quadriparesis and marked cognitive deterioration were identified in two participants after the VA pilot study resumed and following collection of their Trial 2 blood samples. One participant was diagnosed with Amyotrophic Lateral Sclerosis (ALS) in September 2022 and subsequently received care at the Atrium Health Wake Forest Baptist ALS Clinic until his passing. In addition to ALS and quadriparesis, he had two other major comorbid conditions: a diagnosis of “Major or Mild Neurocognitive Disorder due to Unknown Etiology” and metastatic appendiceal cancer. The cancer was diagnosed in December 2019, after his appendix ruptured, approximately 8 months after his enrollment in our study). Serum IgG and IgM human antibody levels against Varicella Zoster dUTPase were positive (elevated) in both of his serum samples (Trials 1 and 2).
A second study participant developed a progressive neurodegenerative disorder characterized by quadriparesis, with partial preservation of the left upper extremity function, and rapidly worsening cognitive impairment. In 2024, he was diagnosed with a “Major or Mild Neurocognitive Disorder due to Unknown Etiology” and was evaluated at Duke University Health Neuromuscular Clinic in August 2025. Additional diagnostic workup is currently underway to establish a more definitive diagnosis. Serologic testing demonstrated persistently elevated IgG antibodies to Varicella Zoster dUTPase in both blood draws (Trials 1 and 2), while elevated IgM antibodies were detected only in the Trial 1 sample.
It is well documented that Varicell a Zoster can damage multiple regions of the central and peripheral nervous system, including upper and lower motor neurons [59,60]. The finding of one study subject with ALS and one other study subject with a neurodegenerative disorder clinically characterized by quadriparesis and a neurocognitive disorder of undetermined etiology would seem at first to be very different from, and unrelated to, chronic multi-symptom illness. Recent research has expanded our understanding of ALS and some other neurodegenerative diseases with respect to the parts of the nervous system affected (i.e., ALS is not just a motor neuron disease).
ALS patients can have symptoms and signs beyond just somatic motor dysfunction [76,77,78,79,80,81,82,83]. These recent articles document an array of symptoms that are common in patients with ALS and in patients with chronic multi-symptom illnesses. A recent article also reviews similarities in immune inflammatory responses found in traditional neuroinflammatory and neurodegenerative disorders, such as Alzheimer’s disease, Parkinson’s disease, and ALS, with those found in chronic multi-symptom illnesses such as Gulf War Illness and myalgic encephalomyelitis [84].
Finally, one previous case report describes the presence of an immunological response in the spinal fluid (CSF) to herpes simplex viruses in a 47-year-old patient diagnosed with ALS, Vulpian–Bernhardt type [85]. A subsequent 12-year follow-up after anti-viral treatment of herpes simplex reported negative antibodies (below the level of measurement) to herpes simplex virus in the CSF and reported the patient doing well clinically [86].
Taken together, these observations suggest several testable hypotheses and research priorities for future studies. Could some idiopathic neurodegenerative disorders such as ALS be just another rare presentation of an inflammatory process in various neurons caused by abortive lytic replication of latent Varicella Zoster or simplex herpes viruses. This possibility may be evaluated using established postmortem tissue analysis methods. Specifically, a previous study examined postmortem brain and spinal cord tissues from a small cohort of individuals with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and found evidence of localized HHV-6 reactivation and EBV dUTPase protein expression in specific neural tissues that were not detected in controls [67]. The authors used fluorescence in situ hybridization (FISH) to detect HHV-6 miR-aU14 (a marker of viral reactivation) and immunofluorescence/confocal microscopy to identify HHV-6 proteins, EBV dUTPase, and cellular inflammatory markers within specific tissues. These techniques could be used to examine similar tissues from individuals who died of ALS or other neurodegenerative diseases. Such studies could determine whether inflammatory herpesvirus dUTPase proteins are present within the central nervous system and whether they may contribute to disease pathogenesis [67].
More direct tests are required to measure inflammatory herpetic virus dUTPase proteins (and possibly other biomarker molecules of early latent viral abortive lytic replication) in the serum, spinal fluid, and tissues/cells of live human bodies. Specifically, assays for measuring both free herpetic virus dUTPase proteins and the combined dUTPase and antibody complex in plasma or spinal fluid may also be needed.
Herpetic dUTPase proteins levels have not yet been assessed in serum using synthesized dUTPase antibodies to capture the unbound herpetic virus dUTPase proteins. The concentration of free or unbound herpetic virus dUTPase proteins in spun-down serum samples may be below the limits of detection using the current assay. Alternatively, it may be possible to use the bottom-up LC-MS (liquid chromatography–tandem mass spectrometry) method to detect free dUTPase protein and dUTPase antibody/protein complexes in samples that are not spun down.
Tissue examination in live humans using imaging techniques may be required to directly identify these selected biomarkers, their quantity, and their location to connect symptoms and signs recorded during a physical exam with a pathological inflammatory process in the body. To accomplish this, an imaging test, perhaps using tagged antibodies introduced into the body, would be necessary. Complicating this process is the possible/probable presence of multiple virus dUTPases causing inflammation at the same time and location or in different locations (cells/tissues) of the nervous system or other tissues of the body.
Finally, questions arise as to what is promoting virus abortive lytic replication and its accompanying inflammation, and whether it is increasing in frequency? Is it caused by a new form of impaired immune system? CMI patients often have low or low-normal serum vitamin D precursor storage levels. Active vitamin D may have a role in the immune system’s suppression of latent herpes viruses and their dUTPase proteins, and in the modulation of the body’s inflammatory response to these herpes virus dUTPase proteins [68,69,70].
To determine the body’s intracellular synthesis of active vitamin D, any fluctuating increase in demand for active vitamin D, and the body’s overall concentration of active vitamin D, a new method of determining these parameters is required [74]. One way to acquire this information may be to measure active vitamin D, 1,25(OH)2D3, and its end metabolites along with its precursor, 25(OH)D3, and its end metabolites in the serum and urine and then back-calculate the level and synthesis of active vitamin D in the body. To achieve this, as with all other clinical tests, lab standards from normal subjects will also have to be determined for the end metabolite values.

5. Study Limitations

This was an observational pilot study with a small number of participants. The goal was to collect pilot study data on many aspects of the 40 study subjects’ physical and mental health and social background.
No control group of Veterans at the W.G. (Bill) Hefner VA Medical Center without chronic multi-symptom illness was used in this study.
Serum inflammatory, antigenic, and herpesvirus dUTPase protein levels were not directly measured; however, human IgG and IgM antibodies to these herpetic virus dUTPase proteins were measured.
The measurement of the active vitamin D precursor, 25(OH)D3, is a measurement of vitamin D precursor storage in the body and, to some extent, the body’s ability to produce active vitamin D, 1,25(OH)2D3 (the battery storage analogy). It does not reflect the body’s actual intracellular active vitamin D concentration, synthesis, utilization, and demand [74].

6. Conclusions

Chronic multi-symptom and system illnesses in the U.S. Veteran population are common, idiopathic, often quite disabling, and are associated with significant physical and psychological suffering despite being generally non-lethal.
In this study, the study subjects often had deficient or insufficient active vitamin D precursor (storage) levels. This deficiency and insufficiency of active vitamin D precursor storage may limit the synthesis of active vitamin D during periods of increased demand [74]. Insufficiency of active vitamin D may impair two of the functions of the immune system, namely the suppression of latent viruses and the modulation/attenuation of the inflammatory response to latent viruses from abortive lytic replication [68,69,70].
Measurable unique dUTPase IgG and IgM dUTPase antibody levels to one of the three subfamilies of human herpetic viruses (VZV, EBV, and HH6V) were present in most of our study subjects in at least one blood draw specimen [17]. The presence of changing IgG and IgM antibodies to the herpetic virus dUTPase proteins is indirect evidence for the presence of an inflammatory immune response to herpes virus dUTPase proteins in our study subjects during this study.
A high percentage of humans are infected with latent herpes virus DNA. Because virus latency is so common, it may be considered a normal state or phenomenon. However, the presence of herpes virus DNA in the body can result in the production of molecules, such as dUTPase proteins, during abortive lytic replication. Herpes virus dUTPase proteins are pathological in humans because they induce an inflammatory response in the cells or tissues where they are present. This is an additional pathological expression of the latent viruses that is different in nature from the regeneration of whole virions, which destroy cells by lysing them (lytic replication) and produce their own inflammatory reaction.
Varicella zoster dUTPase IgM and IgG antibodies were present in the serum of two study subjects who developed severe neurodegenerative disorders, including significant cognitive decline and quadriparesis. These conditions occurred after their initial diagnosis of chronic multi-symptom illness. Alpha herpesviruses (Varicella Zoster and herpes simplex) are known to cause injury to the nervous system, including motor neurons. The capability of latent VZV to infect and inflame motor neurons suggests that abortive lytic replication may be contributing to their idiopathic neurodegenerative disorders.
One of these study subjects (diagnosed and treated for ALS) was a Gulf War Veteran, and both ALS and chronic multi-symptom illness occur more frequently in Gulf War Veterans and are presumptive diagnoses for service connection by the VA.
The following questions remain: When and where (in what tissues/cells) are these antigenic proteins present and how much inflammation are they causing? The locations where latent herpetic viruses reside have been determined for many herpetic viruses using PCR. A physical exam with a focus on the nervous system gives us a clue to where some of the latent herpes virus inflammation might be occurring, especially in the case of herpes zoster.
The simultaneous presence of three different herpesvirus dUTPase protein antibodies in our study subjects suggests that more than one dUTPase protein may be causing inflammation in the same or in different tissues/cells at the same time. This makes determining which one or more of the dUTPase proteins are causing significant inflammation/tissue damage, and in which tissues/cells they are active, a challenge. The presence of human antibodies to the antigenic dUTPase proteins) suggests a new mechanism of chronic viral disease (abortive lytic replication) independent of classical viral lytic replication and lysis of cells.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/pathophysiology33040083/s1, Supplementary S1: Medical History including Medical Diagnoses, Current Medications, Past Physical Trauma, Pertinent Viral infections, and Symptoms (Self-Reported and from the VA Electronic Health Record-EHR); Supplementary S2: Complete Initial Physical Exam Data—Signs.

Author Contributions

N.H.L.C.: Assisted in understanding the vitamin D data, reviewed and edited the manuscript, and contributed to Section 6 of the manuscript. B.C.: Performed lab experiments and reviewed the data at OSU. P.G.: Designed the experiments and the study, performed statistical analyses, wrote and edited the manuscript. S.L.: Performed psychological and cognitive testing and analyzed the data. J.P.: Screened patients for the study, treated study subjects during the study, provided clinical input for the study design and data analysis. I.M.-P.: Performed experiments at OSU and analyzed the data. R.D.S.: Designed the study, performed psychological and cognitive testing, analyzed the data, wrote and edited the manuscript. M.E.A.: Designed the experiments and the study, analyzed the data, wrote and edited the manuscript. M.V.W.: Designed the experiments and the study, analyzed the data, wrote and edited the manuscript. S.R.M.: Designed the experiments and the study, analyzed the data, interviewed and examined the patients, wrote and edited the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding

This study was supported by the National Institutes of Health (NIH/NIAID), Grant R01 AI084898 to M.E.A. and M.V.W., The Salisbury Foundation for Research and Education, and The National Association of Veterans’ Research and Education Foundation, NAVREF.

Institutional Review Board Statement

This study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board and Research Committee of the W.G. (Bill) Hefner VA Medical Center (protocol code IRB Protocol 18-020, Project No. 1575420-4, date of approval: 6 February 2020).

Data Availability Statement

The data that support the findings of this study are available upon request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

Acknowledgments

This study is supported by the U.S. Department of Veterans Affairs, Research Department, W.G. (Bill) Hefner VA Medical Center, Salisbury, NC. We would also like to acknowledge the assistance of Marie Carmen Espiritu for her assistance in screening patients and treating some of the study subjects’ low vitamin D status.

Conflicts of Interest

Sean R. Maloney is a part-time physician employee of the U.S. Government. This study was prepared as part of his official duties. Title 17, USC, 105 provides that “Copyright protection under this title is not available for any work of the U.S. Government”. Title 17, USC, 101 defines a U.S. Government work as “a work prepared by an employee of the U.S. Government as part of that person’s official duties” and is a statement required by the VA to be included in all papers written based in part on research work done at VA Medical Center facilities by VA employees.

References

  1. Public Health: Gulf War Veterans’ Medically Unexplained Illnesses. Department of Veterans Affairs. 16 May 2016. Available online: https://www.publichealth.va.gov/exposure/gulfwar/medically-unexplained-illness.asp (accessed on 30 April 2018).
  2. Cory-Slechta, D.; Wedge, R. (Eds.) Gulf War and Health. In Update of Health Effects of Serving in the Gulf War; The National Academies Press: Washington, DC, USA, 2016; Volume 10. [Google Scholar]
  3. McAndrew, L.M.; Helmer, D.A.; Phillips, L.A.; Chandler, H.K.; Ray, K.; Quigley, K.S. Iraq and Afghanistan Veterans report symptoms consistent with chronic multisymptom illness one year after deployment. J. Rehab Res. Dev. 2016, 53, 59–70. [Google Scholar] [CrossRef] [Scilit]
  4. Smith, T.C.; Powell, T.M.; Jacobson, I.G.; Smith, B.; Hooper, T.M.; Boyko, E.J.; Gacksletter, G.D. Chronic Multisymptom Illness: A Comparison of Iraq and Afghanistan Deployers with Veterans of the 1991 Gulf War. Am. J. Epidemiol. 2014, 180, 1176–1187. [Google Scholar] [CrossRef] [Scilit]
  5. Research Advisory Committee on Gulf War Veterans’ Illnesses. Gulf War Illness and the Health of Gulf War Veterans: Scientific Findings and Recommendations. In Executive Summary: Pg. 4; U.S Government Printing Office: Washington, DC, USA, 2008. Available online: https//www.va.gov./RAC-GWV1/docs/Committee_Documents/GW1andHealthofGWVeterans_RAC-GWVIReport_2008.pdf (accessed on 11 June 2018).
  6. Hyams, K.C.; Wignail, F.S.; Roswell, R. War syndromes and their evaluations: From the U.S. Civil War to the Persian Gulf. Ann. Intern. Med. 1996, 125, 398–405. [Google Scholar] [CrossRef] [Scilit]
  7. Maloney, S.R.; Jensen, S.; Gil-Rivas, V.; Goolkasian, P. Latent viral immune inflammatory response model for chronic multisymptom illness. Med. Hypotheses 2013, 80, 220–229. [Google Scholar] [CrossRef] [Scilit]
  8. Maloney, S.R.; Goolkasian, P. Low Vitamin D States Observed in U.S. Marines and Navy Sailors with Early Multi-Symptom Illness. Biomolecules 2020, 10, 1032. [Google Scholar] [CrossRef] [Scilit]
  9. Ariza, M.E.; Rivailler, P.; Glaser, R.; Chen, M.; Williams, M.V. Epstein-Barr Virus Encoded dUTPase Containing Exosomes Modulate Innate and Adaptive Immune Responses in Human Dendritic Cells and Peripheral Blood Mononuclear Cells. PLoS ONE 2013, 8, e69827. [Google Scholar] [CrossRef] [Scilit]
  10. Aubrecht, T.G.; Weil, Z.M.; Ariza, M.E.; Williams, M.; Reader, B.; Glaser, R.; Sheridan, J.; Nelson, R.J. Epstein-Barr virus (EBV)-Encoded dUTPase and Chronic Restraint Induce Impaired Learning and Memory and Sickness Responses. Physiol. Behav. 2014, 137, 18–24. [Google Scholar] [CrossRef] [Scilit]
  11. Williams, M.V.; Cox, B.; Lafuse, W.P.; Ariza, M.E. Epstein-Barr Virus dUTPase Induces Neuroinflammatory Mediators: Implications for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Clin. Ther. 2019, 41, 848–863. [Google Scholar] [CrossRef] [Scilit]
  12. Ariza, M.E.; Glaser, R.; Williams, M.V. Human herpesviruses-encoded dUTPases: A family of proteins that modulate dendritic cell function and innate immunity. Front. Microbiol. Virol. 2014, 5, 505. [Google Scholar] [CrossRef] [Scilit]
  13. Williams, M.V.; Brandon, C.; Ariza, M.E. Herpesviruses dUTPases: A New Family of Pathogen-Associated Molecular Pattern (PAMP) Proteins with Implications for Human Disease. Pathogens 2017, 6, 2. [Google Scholar] [CrossRef] [Scilit]
  14. Ariza, E.A. Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: The Human Herpesviruses Are Back! Biomolecules 2021, 11, 185. [Google Scholar] [CrossRef] [Scilit]
  15. Ariza, M.E.; Cox, B.; Martinez, B.; Mena-Polomo, I.; Zarate, G.J.; Williams, M.V. Viral dUTPases: Modulators of Innate Immunity. Biomolecules 2022, 12, 227. [Google Scholar] [CrossRef] [Scilit]
  16. Cox, B.; Goolkasian, P.; Palomo, I.M.; Williams, M.V.; Maloney, S.R.; Ariza, M.E. Reactivation of Latent Herpesviruses and a Faulty Antiviral Response may Contribute to Chronic Multi-Symptom and Multi-System Illnesses in U.S. Military Veterans. J. Med. Virol. 2025, 97, e70400. [Google Scholar] [CrossRef] [Scilit]
  17. Vertessy, B.G.; Toth, J. Keeping Uracil Out of DNA: Physiological Role, Structure, and Catalytic Mechanism of dUTPases. Acc. Chem. Res. 2009, 42, 97–106. [Google Scholar] [CrossRef] [Scilit]
  18. SoRelle, E.D.; Haynes, L.E.; Willard, K.A.; Chang, B.; Ch’ng, J.; Christofk, H.; Luftig, M.A. Epstein-Barr virus reactivation induces divergent abortive, reprogrammed, and host shutoff states by lytic progression. PLoS Pathog. 2024, 20, e1012341. [Google Scholar] [CrossRef] [Scilit]
  19. Weidner-Glunde, M.; Kruminis-Kaszkiel, E.; Savanagouder, M. Herpesviral Latency—Common Themes. Pathogens 2020, 9, 125. [Google Scholar] [CrossRef] [Scilit]
  20. Cohen, J.I. Herpesvirus latency. J. Clin. Investig. 2020, 130, 3361–3369. [Google Scholar] [CrossRef] [Scilit]
  21. Stoeger, T.; Adler, H. “Novel” Triggers of Herpesvirus Reactivation and Their Potential Health Relevance. Front. Microbiol. 2019, 9, 3207. [Google Scholar] [CrossRef] [Scilit]
  22. Laichalk, L.L.; Thorley-Lawson, D.A. Terminal differentiation into plasma cells initiates the replicative cycle of Epstein-Barr virus in vivo. J. Virol. 2005, 79, 1296–1307. [Google Scholar] [CrossRef] [Scilit]
  23. Al Tabaa, Y.; Tuaillon, E.; Bollore, K.; Foulongne, V.; Petitjean, G.; Seigneurin, J.M.; Duperray, C.; Desgranges, C.; Vendrell, J.P. Functional Epstein-Barr virus reservoir in plasma cells derived from infected blood memory B cells. Blood 2009, 113, 604–611. [Google Scholar] [CrossRef] [Scilit]
  24. Al Tabaa, Y.; Tuaillon, E.; Jeziorski, E.; Ouedraogo, D.E.; Bollore, K.; Rubbo, P.A.; Foulongne, V.; Rodiere, M.; Vendrell, J.P. B-cell polyclonal activation and Epstein-Barr viral abortive lytic cycle are two key features in acute infectious mononucleosis. J. Clin. Virol. 2011, 52, 33–37. [Google Scholar] [CrossRef] [Scilit]
  25. Altmann, M.; Hammerschmidt, W. Epstein-Barr virus provides a new paradigm: A requirement for the immediate inhibition of apoptosis. PLoS Biol. 2005, 3, e404. [Google Scholar] [CrossRef] [Scilit]
  26. Wen, W.; Iwakiri, D.; Yamamoto, K.; Maruo, S.; Kanda, T.; Takada, K. Epstein-Barr virus BZLF1 gene, a switch from latency to lytic replication, is expressed as an immediate-early gene after primary infection of B lymphocytes. J. Virol. 2007, 81, 1037–1042. [Google Scholar] [CrossRef] [Scilit]
  27. Shannon-Lowe, C.; Adland, E.; Bell, A.I.; Delecluse, H.J.; Rickman, A.B.; Rowe, M. Features distinguishing Epstein-Barr virus infections of epithelial cells and B cells: Viral genome expression, genome maintenance, and genome amplification. J. Virol. 2009, 83, 7749–7760. [Google Scholar] [CrossRef] [Scilit]
  28. Kalla, M.; Hammerschmidt, W. Human B cells on their route to latent infection-early but transient expression of lytic genes of Epstein-Barr virus. Eur. J. Cell Biol. 2012, 91, 65–69. [Google Scholar] [CrossRef] [Scilit]
  29. Perez, L. Characterizing cytomegalovirus infection one cell at a time. Nat. Microbiol. 2021, 6, 1477–1478. [Google Scholar] [CrossRef] [Scilit]
  30. Hein, M.Y.; Weissman, J.S. Functional single-cell genomics of human cytomegalovirus infection. Nat. Biotechnol. 2022, 40, 391–401. [Google Scholar] [CrossRef] [Scilit]
  31. Prusty, B.K.; Gulve, N.; Chowdhury, S.R.; Schuster, M.; Strempel, S.; Descamps, V.; Rudel, T. HHV-6 encoded small non-coding RNAs define an immediate and early stage in viral replication. Genom. Med. 2018, 3, 25. [Google Scholar] [CrossRef] [Scilit]
  32. Scholz, B.A.; Harth-Hertle, M.L.; Malterer, G.; Haas, J.; Ellwart, J.; Schulz, T.F.; Kempkes, B. Abortive lytic reactivation of KSHV in CBF1/CSL deficient human cell lines. PLoS Pathog. 2013, 9, e1003336. [Google Scholar] [CrossRef] [Scilit]
  33. Campbell, D.M.; Rappocciolo, G.; Jenkins, F.J.; Rinaldo, C.R. Dendritic cells: Key players in human herpesvirus 8 infection and pathogenesis. Front. Microbiol. 2014, 5, 452. [Google Scholar] [CrossRef] [Scilit]
  34. Aneja, K.K.; Yuan, Y. Reactivation and lytic replication of Kaposi’s sarcoma-associated herpesvirus: An update. Front. Microbiol. 2017, 8, 613. [Google Scholar] [CrossRef] [Scilit]
  35. Ma, J.Z.; Russell, T.A.; Spelman, T.; Carbone, F.R.; Tscharke, D.C. Lytic replication is frequent in HSV-1 latent infection and correlates with the engagement of a cell-intrinsic transcriptional response. PLoS Pathog. 2014, 10, e1004237, Correction in PLoS Pathog. 2014, 10, e1004361. https://doi.org/10.1371/journal.ppat.1004361. [Google Scholar] [CrossRef] [Scilit]
  36. Drayman, N.; Patel, P.; Vistain, L.; Tay, S. HSV-1 single cell analysis reveals the activtion of anti-viral and developmental programs in distinct sub-populations. Elife 2019, 8, e46339. [Google Scholar] [CrossRef] [Scilit]
  37. Kobiler, O.; Afriat, A. The fate of incoming HSV-1 genomes entering the nucleus. Curr. Issues Mol. Biol. 2021, 41, 221–266. [Google Scholar] [CrossRef] [Scilit]
  38. Fredrikson, J.P.; Domanico, L.F.; Pratt, S.L.; Loveday, E.K.; Taylor, M.P.; Chang, C.B. Single-cell herpes simplex virus type 1 infection of neyrons usingdrop-based microfluidics reveals heterogeneous replication kinetics. Sci. Adv. 2024, 10, eadk9185. [Google Scholar] [CrossRef] [Scilit]
  39. Laemmie, L.; Goldstein, R.S.; Kinchington, P.R. Modeling Varicella zoster virus persistence and reactivation-closer to resolving a perplexing persistent state. Front. Microbiol. 2019, 10, 1634. [Google Scholar] [CrossRef] [Scilit]
  40. Warner, B.E.; Yee, M.B.; Zhang, M.; Hornung, R.S.; Kaufer, B.B.; Visalli, R.J.; Kramer, P.R.; Goins, W.F.; Kinchington, P.R. Varicella-zoster virus early infection but not complete replication is required for the induction of chronic hypersensitivity in rat models of postherpetic neuralgia. PLoS Pathog. 2021, 17, e1009689. [Google Scholar] [CrossRef] [Scilit]
  41. Wang, J.; Bruckner, N.; Weissmann, S.; Gunther, T.; Zhu, S.; Vogt, C.; Sun, G.; Guo, R.; Bruno, R.; Ritter, B.; et al. Repression of varicella zoster gene express during quiescent infection in the absence of detectable histone deposition. PLoS Pathog. 2025, 21, e1012367. [Google Scholar] [CrossRef] [Scilit]
  42. Nasreddine, Z.S.; Phillips, N.A.; Bédirian, V.; Charbonneau, S.; Whitehead, V.; Collin, I.; Cummings, J.L.; Chertkow, H. The Montreal Cognitive Assessment, MoCA: A brief screening tool for mild cognitive impairment. J. Am. Geriatr. Soc. 2005, 53, 695–699. [Google Scholar] [CrossRef] [Scilit]
  43. Rossetti, H.C.; Lacritz, L.H.; Cullum, C.M.; Weiner, M.F. Normative data for the Montreal Cognitive Assessment (MoCA) in a population-based sample. Neurology 2011, 77, 1272–1275. [Google Scholar] [CrossRef] [Scilit]
  44. Conners, K. Conners Continuous Performance Test, 3rd ed.; (CPT-3); MHS Inc.: Toronto, ON, Canada, 2014. [Google Scholar]
  45. Mahoney, M.R.; Farmer, C.; Sinclair, S.; Sung, S.; Dehaut, K.; Chung, J.Y. Utilization of the DSM-5 Self-Rated Level 1 Cross-Cutting Symptom Measure-Adult to Screen Healthy Volunteers for Research Studies. Psychiatry Res. 2020, 286, 112822. [Google Scholar] [CrossRef] [Scilit]
  46. American Psychiatric Association. DSM-5 Self Rated Somatic Symptoms Level 2, Adult; American Psychiatric Association: Washington, DC, USA, 2013; Available online: https://www.psychiatry.org/psychiatrists/practice/dsm/educational-resources/assessment-measures/ (accessed on 15 October 2025).
  47. American Psychiatric Association. DSM-5 Self Rated Anxiety Scale Level 2, Adult; American Psychiatric Association: Washington, DC, USA, 2013; Available online: https://www.psychiatry.org/getcontentasset/538a62c3-2e1e-4bc3-bafd-7a02efad4937/dfc3d011-8f63-43f6-9ed8-4b444333a1d0/apa-dsm5tr-severitymeasureforseparationanxietydisorderadult?language=en (accessed on 15 October 2025).
  48. King, P.R., Jr. A Psychometric Study of the Neurobehavioral Symptom Inventory; ProQuest Information & Learning: Ann Arbor, MI, USA, 2012. [Google Scholar]
  49. Cooper, D.B.; Nelson, L.; Armistead-Jehle, P.; Bowles, A.O. Utility of the Mild Brain Injury Atypical Symptoms Scale as a screening measure for symptom over-reporting in Operation Enduring Freedom/Operation Iraqi Freedom service members with post-concussive complaints. Arch. Clin. Neuropsychol. 2011, 26, 718–727. [Google Scholar] [CrossRef] [Scilit]
  50. Buysse, D.J.; Reynolds, C.F.; Monk, T.H.; Berman, S.R.; Kupfer, D.J. The Pittsburgh Sleep Quality Index: A new instrument for psychiatric practice and research. Psychiatry Res. 1989, 28, 193–213. [Google Scholar] [CrossRef] [Scilit]
  51. National Center for Veteran’s Analysis and Statistics; United States Department of Veterans Affairs. Profile of Veterans: 2016 Data from the American Community Survey; United States Department of Veterans Affairs: Washington, DC, USA, 2018; pp. 1–45. [Google Scholar]
  52. Census Bureau Releases New Report on Veterans, Press Release Number CB20-TPS.30, 2 June 2020, US Census Bureau, US Government. Available online: https://www.census.gov/newsroom/press-releases/2020/veterans-report.html (accessed on 20 December 2023).
  53. VetPop2020 National Data, 1L, National Center for Veterans Analysis and Statistics, US Department of Veterans Affairs. Available online: https://www.data.va.gov/dataset/VetPop2020-National-Data-1L/8sxc-5kzr/data_preview (accessed on 20 December 2023).
  54. Deployment, Combat, and Their Consequences. The American Veteran Experience and the Post-9/11 Generation. Pew Research Center. 10 September 2019. Available online: https://www.pewresearch.org/social-trends/2019/09/10/deployment-combat-and-their-consequences/ (accessed on 7 November 2023).
  55. Minority Veteran Statistics, Population Page, Racial and Ethnic Minority. In Veterans; Office of Health Equity, U.S. Dept. of Veterans Affairs: Washington, DC, USA, 2016. Available online: https://www.va.gov/HEALTHEQUITY/Race_Ethnicity.asp (accessed on 27 February 2021).
  56. Military Service Experience, VA.gov Home, VA Dept. of Veterans Affairs. Available online: https://www.va.gov/vetdata/docs/surveysandstudies/military.pdf (accessed on 15 February 2024).
  57. WebMD. Hypertension-High Blood Pressure Guide: Diastolic and systolic. Available online: https://www.webmd.com/hypertension-high-blood-pressure/diastolic-and-systolic-blood-pressure-know-your-numbers (accessed on 10 March 2021).
  58. Maule, A.L.; Janulewicz, P.A.; Sullivan, K.A.; Krengel, M.H.; Yee, M.K.; McClean, M.; White, R.F. Meta-analysis of self-reported health symptoms in 1990-1991 Gulf War and Gulf War-era veterans. BMJ Open 2018, 8, e016086. [Google Scholar] [CrossRef] [Scilit]
  59. Kennedy, P.G.E. The Spectrum of Neurological Manifestations of Varicella-Zoster Virus Reactivation. Viruses 2023, 15, 1663. [Google Scholar] [CrossRef] [Scilit]
  60. Gilden, D.; Nagel, M.; Cohrs, R.; Mahalingam, R.; Baird, N. Varicella Zoster Virus in the Nervous System. F1000Research 2015, 4, 1356. [Google Scholar] [CrossRef] [Scilit]
  61. Nair, P.A.; Patel, B.C. Herpes Zoster. In Stat Pearls, NCBI Bookshelf; National Library of Medicine: Bethesda, MD, USA, 2023. [Google Scholar]
  62. Zhou, J.; Li, J.; Ma, L.; Cao, S. Zoster sine herpete: A review. Korean J. Pain 2020, 3, 208–215. [Google Scholar] [CrossRef] [Scilit]
  63. Haanpa, M.; Laippala, P.; Nurmikko, T. Allodynia and Pinprick Hypesthesia in Acute Herpes Zoster, and the Development of Postherpetic Neuralgia. J. Pain Symptom Manag. 2000, 20, 50–58. [Google Scholar] [CrossRef] [Scilit]
  64. Jain, E.; Eldon, E.; Witkin, L.; Cron, J. Herpes Simplex Virus-1 Complicated by Postherpetic Neuralgia: A Case Report. Pain Med. Case Rep. 2024, 8, 133–136. [Google Scholar] [CrossRef] [Scilit]
  65. Theil, D.; Arbusow, V.; Derfuss, T.; Strupp, M.; Pfeiffer, M.; Mascolo, A.; Brandt, T. Prevalence of HSV-1 latency in human Trigeminal geniculate, and vestibular ganglia and its implications for cranial nerve syndromes. Brain Pathol. 2001, 11, 408–413. [Google Scholar] [CrossRef] [Scilit]
  66. Daruish, M.; Cazzato, G.; Markiewics, D.; Taibjee, S.; Fortarezza, F.; Calonje, E. A Review of Atypical Cutaneous histological Manifestations of Herpes Zoster. Viruses 2024, 16, 1035. [Google Scholar] [CrossRef] [Scilit]
  67. Kasimir, F.; Toomey, D.; Liu, Z.; Kaiping, A.C.; Ariza, M.E.; Prusty, B.K. Tissue specific signature of HHV-6 infection in ME/CFS. Front. Mol. Biosci. 2022, 9, 1044964. [Google Scholar] [CrossRef] [Scilit]
  68. Hewsin, M. Vitamin D and the intracrinology of innate immunity. Mol. Cell Endocrinol. 2010, 321, 103–111. [Google Scholar] [CrossRef] [Scilit]
  69. White, J.H. Emerging Roles of Vitamin D-Induced Antimicrobial Peptides in Antiviral Innate Immunity. Nutrients 2022, 14, 284. [Google Scholar] [CrossRef] [Scilit]
  70. Galdo-Torres, D.; Andreu, S.; Caballero, O.; Hernandez-Ruiz, I.; Ripa, I.; Bello-Morales, R.; Lopez-Guerrero, J.A. Immune Modulatory Effects of Vitamin D on Herpesvirus Infections. Int. J. Mol. Sci. 2025, 26, 1767. [Google Scholar] [CrossRef] [Scilit]
  71. Holick, M.F.; Binkley, N.C.; Bischo-Ferrari, H.A.; Gordon, C.M.; Hanley, D.A.; Heaney, R.P.; Murad, M.H.; Weaver, C.M. Evaluation, Treatment, and Prevention of Vitamin D Deficiency: An Endocrine Society Clinical Practice Guideline. J. Clin. Endocrinol. Metab. 2011, 96, 1911–1930, Correction in J. Clin. Endocrinol. Metab. 2011, 96, 3908. Correction in J. Clin. Endocrinol. Metab. 2024, 109, 1991. [Google Scholar] [CrossRef] [Scilit]
  72. Kidney Research Institute, University of Washington. 25 Hydroxyvitamin D Calculator for Seasonal Adjustment. Available online: https://kri.washington.edu/research/tools (accessed on 31 January 2019).
  73. Sachs, M.C.; Shoben, A.; Levin, G.P.; Robinson-Cohen, C.; Hoofnagle, A.N.; Swords-Jenny, N.; Ix, J.H.; Budoff, M.; Lutsey, P.L.; Siscovick, D.S.; et al. Estimating mean annual 25-hydroxyvitamin D concentrations from single measurements: The Multi-Ethnic Study of Atherosclerosis. Am. J. Clin. Nutr. 2013, 97, 1243–1251. [Google Scholar] [CrossRef] [Scilit]
  74. Maloney, S.R. A Mathematical Model for Determining the Body’s Fluctuating Need for and Synthesis of Active Vitamin D. Biomedicines 2023, 11, 324. [Google Scholar] [CrossRef] [Scilit]
  75. Bischoff-Ferrari, H.A.; Kiel, D.P.; Dawson-Hughes, B.; Orav, J.E.; Li, R.; Spiegelman, D.; Dietrich, T.; Willett, W.C. Dietary Calcium and Serum 25-Hydroxyvitamin D Status in Relation to BMD Among U.S. Adults. J. Bone Min. Res. 2008, 24, 935–942. [Google Scholar] [CrossRef] [Scilit]
  76. Bombaci, A.; Lupica, A.; Pozzi, F.E.; Remoli, G.; Manera, U.; Di Stefano, V. Sensory neuropathy in amyotrophic lateral sclerosis: A systemic review. J. Neurol. 2023, 270, 5677–5691. [Google Scholar] [CrossRef] [Scilit]
  77. Rubio, M.A.; Herrando-Grabulosa, M.; Navarro, X. Sensory Involvement in Amyotrophic Lateral Sclerosis. Int. J. Mol. Sci. 2022, 23, 15521. [Google Scholar] [CrossRef] [Scilit]
  78. Riancho, J.; Paz-Fajordo, L.; de Munain, A. Clinical and preclinical evidence of somatosensory involvement in amyotrophic lateral sclerosis. Br. J. Pharmacol. 2021, 178, 1257–1268. [Google Scholar] [CrossRef] [Scilit]
  79. Dubbioso, R.; Provitera, V.; Pacella, D.; Santoro, L.; Manganelli, F.; Nolano, M. Autonomic dysfunction is associated with disease progression and survival in amyotrophic lateral sclerosis: A prospective longitudinal cohort study. J. Neurol. 2023, 270, 4968–4977. [Google Scholar] [CrossRef] [Scilit]
  80. Oprisan, A.L.; Popescu, B.O. Dysautonomia in Amyotrophic Lateral Sclerosis. Int. J. Mol. Sci. 2023, 24, 14927. [Google Scholar] [CrossRef] [Scilit]
  81. Chio, A.; Mora, G.; Lauria, G. Pain in amyotrophic lateral sclerosis. Lancet Neurol. 2017, 16, 144–157. [Google Scholar] [CrossRef] [Scilit]
  82. Alencar, M.A.; Soares, B.L.; de Andrade Rangel, M.F.; Abdo, J.S.; de Almeida, R.A.P.; de Araujo, C.M.; de Souza, L.C.; de Cassia Gomes, G. Fatigue in amyotrophic lateral sclerosis and correlated factors. Arq. Neuropsiquiatr. 2022, 80, 1045–1051. [Google Scholar] [CrossRef] [Scilit]
  83. Bjelica, B.; Bartels, M.-B.; Hesebeck-Brinckmann, J.; Petri, S. Non-motor symptoms in patients with amyotrophic lateral sclerosis: Current state and future directions. J. Neurol. 2024, 271, 3953–3977. [Google Scholar] [CrossRef] [Scilit]
  84. Cohen, J.; Mathew, A.; Dourvetakis, K.D.; Sanchez-Guerrero, E.; Pangeni, R.P.; Gurusamy, N.; Aenlle, K.K.; Ravindran, G.; Twahir, A.; Isler, D.; et al. Recent Research Trends in Neurodegenerative Disorders. Cells 2024, 13, 511. [Google Scholar] [CrossRef] [Scilit]
  85. Ferri-de-Barros, J.E.; Moreira, M. Amyotrophic lateral sclerosis and herpes virus. Report of an unusual case: A cause or casual association? Arq. Neuropsiquiatr. 1998, 56, 307–311. [Google Scholar]
  86. Ferri-de-Barros, J.E.; Moreira, M. Amyotrophic lateral sclerosis and herpes virus: A casual or causal association? Twelve years after. Arq. Neuropsiquiatr. 2010, 68, 978–979. [Google Scholar] [CrossRef] [Scilit]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.